ImmunoEdge

"Unlocking a broader immune target landscape" from routine biopsies by recovering HLA-presented tumor peptides that standard workflows systematically miss.

Where it wins

• Recovers peptides from ultra-low-input biopsies where affinity-based methods lose up to 99% of targets [1].
• Enables longitudinal studies by supporting multiple analyses from minimal sample material, unlike single-shot standard workflows [1].
• Reduces R&D uncertainty by revealing low-expression but immune-visible peptides that genome-based predictions overlook [1].

Credibility: Founder Mogjib Salek PhD led neoepitope discovery at DKFZ/NCT Heidelberg, identifying immunoprecipitation's limitations for clinical samples [1].

• Platform licensing and partnerships: Developing a low-loss immunopeptidomics platform with novel capture chemistry to be used by research and clinical teams [1].
• Service-based revenue: Offering pilot collaborations and co-development opportunities for translational studies [1].
• Scalability: Designed to work with routine core biopsies, enabling broader applicability across tumor sites and clinical timepoints [1].

• Standard immunopeptidomics workflows: Rely on affinity-based methods that introduce sample loss and bias, especially with low-input material [1].
• Genome-based prediction tools: Overlook low-expression peptides, creating blind spots in target discovery [1].
• Differentiators: ImmunoEdge's novel capture chemistry enables broader peptide recovery from routine biopsies, supporting longitudinal studies and reducing R&D uncertainty [1].

• High sample loss: Standard immunopeptidomics workflows lose up to 99% of tumor immunopeptides from small biopsies [1].
• Limited longitudinal analysis: Current methods require large samples and allow only single analyses, hindering real-world applicability [1].
• Blind spots in predictions: Genome-based methods miss low-expression but immune-visible peptides, creating gaps in therapeutic planning [1].

ImmunoEdge's focus on ultra-low-input biopsies addresses a critical gap in immunopeptidomics, enabling broader target discovery from routine clinical samples. The main risk is the transition from pre-commercial development to commercial services, which requires validation and regulatory approval. The opportunity lies in partnering with biotech and pharma companies to de-risk immunotherapy development. The next signal to watch is the outcome of pilot collaborations and co-development partnerships, which will validate the platform's efficacy and scalability.

ImmunoEdge should prioritize securing pilot collaborations with leading academic and industry partners to validate the platform's efficacy in real-world clinical samples. Interconnection: This validation is critical for transitioning from pre-commercial development to commercial services. The company should develop a clear pathway for regulatory approval and commercialization, including engagement with health authorities and potential customers. Interconnection: This will help de-risk the transition and build confidence among potential partners. ImmunoEdge should expand its advisory board to include experts in regulatory affairs and commercialization, enhancing its ability to navigate the path to market. Interconnection: This will strengthen the company's strategic execution and partnership development.